summit study tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity Interplay of Chronic Kidney Disease

Investors will hear initial sales figures when Novo reports first quarter earnings on May 6

Developing orally administered non-peptide GLP-1 receptor agonists requires sophisticated drug discovery and formulation technologies to achieve adequate oral bioavailability, therapeutic efficacy, and pharmacokinetic performance comparable to injectable GLP-1 therapies

Semaglutide slows down the movement of food from the stomach to your small intestine, causing food to stay in your stomach for a longer time (delayed gastric emptying), which can cause feelings of fullness and discomfort

TAA-compliant video wall processors from Jupiter Systems power mission-critical control rooms across U.S